Trial Profile
A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cintirorgon (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Renal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms ARGON
- Sponsors Lycera
- 24 Sep 2019 Status changed from recruiting to completed.
- 28 Feb 2019 Results of the phase 1 portion of the study (As of May 2018; n=32), published in the Clinical Cancer Research
- 10 Oct 2018 According to a Lycera media release, data from this study will be presnted at 2018 European Society for Medical Oncology (ESMO) Congress.